Clinical trials: Inflammatory Disorder
Ulcerative Colitis (UC)
A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis
The goal of this clinical trial is to learn if MB-001, an oral biologic, is able to treat patients with ulcerative colitis. Participants will be asked to take MB-001 or a matching placebo once-daily for a period of 12 weeks.
- Trial name
- NCT07374471
- Testing
- MB-001
- Where
- 7 sites in Georgia, Moldova and 2 more
- Volunteers
- 100 people
- Sponsor
- Mage Biologics
Crohn's Disease
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug).
- Trial name
- OPERA (NCT01276509)
- Testing
- PF-00547659 SC injection
- Where
- 137 sites in United States, Austria and 14 more
- Volunteers
- 265 people
- Sponsor
- Shire
Crohns Disease, Fistula
A Study of Surgical Interventions in Fistulizing Conditions
In this study, participants with complex fistulizing conditions will be treated with surgical interventions according to their clinic's standard practice.
- Conditions
- Crohns Disease, Fistula, Rectovaginal Fistula, Complex Perianal Fistula
- Trial name
- NCT04940611
- Where
- 41 sites in United States, Austria and 8 more
- Volunteers
- 646 people
- Sponsor
- Takeda
Colitis, Ulcerative
Combined Nutritional Therapies for the Treatment of Ulcerative Colitis
Ulcerative colitis (UC) is an entity of complex etiology where environmental, genetic and intestinal microflora-related factors trigger and perpetuate a chronic inflammation of the gastrointestinal tract.
- Trial name
- NCT03444311
- Testing
- A: 1 dosis, B: 2 dosis
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- AB Biotics, SA
Crohn's Disease
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently…
- Trial name
- NCT00055536
- Testing
- natalizumab
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Crohn's Disease
A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects
This is an open-label, single dose, randomized, five-period, crossover study in healthy volunteers to assess the relative bioavailability of four GSK developed oral formulations of GSK1605786 relative to the capsule formulation…
- Trial name
- NCT01114607
- Testing
- GSK1605786 ChemoCentryx: formulation A, GSK1605786 GSK: formulation B, GSK1605786 GSK direct-fill: formulation C
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sepsis, Adult Disease
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in…
- Conditions
- Sepsis, Adult Disease, Emergency Department, Severe Sepsis
- Trial name
- NCT04804306
- Testing
- Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Beckman Coulter, Inc.
Colitis, Ulcerative, Crohn Disease
A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate how long participants with moderate-to-severe Crohn's Disease (CD) and Ulcerative Colitis (UC) continue treatment with guselkumab in a real-world setting.
- Trial name
- GALILEO (NCT07848737)
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Janssen-Cilag, S.A.
Avascular Necrosis of Hip, Osteoarthritis, Hip
Metasul Monoblock Component™ Cup in a Hip Resurfacing Application With the Durom® Hip Resurfacing Femoral Component
The Zimmer Hip Resurfacing System Post-Market Clinical Follow-up study will examine the safety and efficacy of this device in the young and/or active patient with advanced hip disease.
- Conditions
- Avascular Necrosis of Hip, Osteoarthritis, Hip, Rheumatoid Arthritis, Inflammatory Arthritis
- Trial name
- MMC (NCT03681639)
- Testing
- Serum Metal ion levels determined to monitor changes in chromium and cobalt levels
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Zimmer Biomet
Crohn's Disease
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive…
- Trial name
- DIVERSITY1 (NCT02914561)
- Testing
- Filgotinib
- Where
- 513 sites in United States, Argentina and 39 more
- Volunteers
- 1,372 people
- Sponsor
- Lakefront Biotherapeutics NV
Uncontrolled Asthma
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy
The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)
- Trial name
- TANGO (NCT06029595)
- Testing
- Experimental: CHF6001 3200 μg
- Where
- 187 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 517 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Colitis, Ulcerative
Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients
The study will investigate efficacy of STW5-II as add-on therapy on the rate to remission in patients with mild to moderate ulcerative colitis in an acute flare.
- Trial name
- NCT02246686
- Testing
- STW5-II (Iberogast N, BAY98-7410)
- Where
- 8 sites in Germany
- Volunteers
- 3 people
- Sponsor
- Bayer
Dermatomyositis, Polymyositis
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]).
- Trial name
- NCT06698796
- Testing
- Dazukibart
- Where
- 26 sites in United States, Argentina and 10 more
- Volunteers
- 211 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD
CHF6297 is a potent and selective inhibitor of human MAP kinase p38 being developed as an anti-inflammatory agent for the treatment of inflammatory airways diseases.
- Trial name
- CHF6297 FIH (NCT02815488)
- Testing
- CHF6297 (Part 1 - SAD), CHF6297 (Part 2 - MAD), CHF6297 (Part 3)
- Where
- 2 sites in United Kingdom
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Crohn Disease
A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease
A study of infliximab in patients with Fistulizing Crohn's Disease
- Trial name
- NCT00207766
- Volunteers
- 306 people
- Sponsor
- Centocor, Inc.
Sepsis, Disseminated Intravascular Coagulation
Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation
The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.
- Trial name
- NCT00487656
- Testing
- ART-123
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 750 people
- Sponsor
- Artisan Pharma, Inc.
Coronary Artery Disease
Genetic Polymorphisms Associated With CAD
The design and purpose of the current study is to expand and validate previous findings that the IL-1 gene cluster composite genotype patterns potentiate the risk for coronary artery disease (CAD) and cardiovascular events…
- Trial name
- NCT02307422
- Testing
- IL-1 Genotypes, other SNPs associated with CAD
- Volunteers
- 1,173 people
- Sponsor
- Interleukin Genetics, Inc.
Colitis, Ulcerative
An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with active ulcerative colitis, who are being…
- Trial name
- NCT00463151
- Testing
- rebamipide
- Where
- 5 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Ulcerative Colitis, Inflammatory Bowel Diseases
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
Protocol Summary Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative…
- Trial name
- NCT05176366
- Testing
- ExoFlo
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Direct Biologics, LLC
Colitis, Ulcerative
Budesonide 9 mg Capsules in Active UC
The purpose of the trial is to evaluate the efficacy of an 8 week treatment with once-daily 9 mg budesonide in patients with active ulcerative colitis
- Trial name
- TOPICAL-1 (NCT02550418)
- Testing
- Budesonide
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Dr. Falk Pharma GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.